Probabilistic Analysis and Computationally Expensive Models: Necessary and Required?  by Griffin, Susan et al.
Volume 9 • Number 4 • 2006
V A L U E  I N  H E A L T H
244 © 2006, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/06/244 244–252
10.1111/j.1524-4733.2006.00107.x
Blackwell Publishing IncMalden, USAVHEValue in Health1098-30152006 Blackwell Publishing200694244252Original ArticlePSA and Computationally Expensive ModelsGrifﬁn et al.
Address correspondence to: Susan Grifﬁn, Alcuin A Block,
University of York, Heslington, York YO10 5DD, UK. E-mail:
scg3@york.ac.uk
Probabilistic Analysis and Computationally Expensive Models: 
Necessary and Required?
Susan Grifﬁn, MSc, Karl Claxton, PhD, Neil Hawkins, PhD, Mark Sculpher, PhD
Center for Health Economics, University of York, York, UK
ABSTRACT
Objective: To assess the importance of considering decision
uncertainty, the appropriateness of probabilistic sensitivity
analysis (PSA), and the use of patient-level simulation (PLS)
in appraisals for the National Institute for Health and Clin-
ical Excellence (NICE).
Methods: Decision-makers require estimates of decision
uncertainty alongside expected net beneﬁts (NB) of interven-
tions. This requirement may be difﬁcult in computationally
expensive models, for example, those employing PLS. NICE
appraisals published up until January 2005 were reviewed to
identify those where the assessment group utilized a PLS
model structure to estimate NB. After identifying PLS mod-
els, all appraisals published in the same year were reviewed.
Results: Among models using PLS, one out of six conducted
PSA, compared with 16 out of 24 cohort models. Justiﬁca-
tion for omitting PSA was absent in most cases. Reasons for
choosing PLS included treatment switching, sampling patient
characteristics and dependence on patient history. Alterna-
tive modeling approaches exist to handle these, including
semi-Markov models and emulators that eliminate the need
for two-level simulation. Stochastic treatment switching and
sampling baseline characteristics do not inform adoption
decisions. Modeling patient history does not necessitate PLS,
and can depend on the software used. PLS addresses nonlin-
ear relationships between patient variability and model out-
puts, but other options exist. Increased computing power,
emulators or closed-form approximations can facilitate PSA
in computationally expensive models.
Conclusions: In developing models analysts should consider
the dual requirement of estimating expected NB and charac-
terizing decision uncertainty. It is possible to develop models
that meet these requirements within the constraints set by
decision-makers.
Keywords: cost-effectiveness analysis, decision uncertainty,
decision-analytic modeling, patient-level simulation, proba-
bilistic analysis.
Introduction
Economic evaluation of health-care technologies is
increasingly recommended internationally for inform-
ing the allocation of health-care resources [1]. For
almost every set of technologies considered, it will be
necessary to combine information on costs and effects
from several sources, and modeling techniques will be
employed. When building any decision model, it is
important to consider how to handle uncertainty and
variability, because these affect the value and interpre-
tation of the model output. Decision-makers require
unbiased estimates of the costs and effects of alterna-
tive interventions for identiﬁable patient groups, and
the ability of a model structure to provide these can
depend on how uncertainty, variability, and heteroge-
neity are handled in the structure. There is also a need
to provide an assessment of whether current evidence
is sufﬁcient to support the decision to adopt a technol-
ogy. By formally estimating decision uncertainty, the
value of obtaining additional information on model
parameters can be assessed [2–4].
In this article we explore methods available to
address uncertainty, variability, and heterogeneity
within decision models. We explore how the current
methods for conducting probabilistic sensitivity anal-
ysis (PSA) to characterize decision uncertainty can con-
ﬂict with the use of computationally expensive model
structures. The premise is that the purpose of a
decision model is to provide unbiased estimates of
expected cost and effects, and of decision uncertainty,
in a timely fashion and within resource constraints as
determined by the decision-maker that commissions
the model. In this article, the focus is on one particular
decision-maker, the National Institute for Health and
Clinical Excellence (NICE) in the UK. This focus has a
number of advantages: 1) NICE is an agency with a
history of using decision-analytic cost-effectiveness
models as a basis for deciding whether to support the
use of particular health-care technologies in the UK
National Health Service (NHS) [5]; 2) by focusing on
a single decision-maker, the case studies identiﬁed in
the review will have been developed with consistent
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time and resource constraints; 3) NICE has speciﬁed a
reference case that deﬁnes those methods considered
most appropriate for informing decisions about the
adoption of new technologies [6], which makes the
case studies identiﬁed in the review comparable in this
respect; and 4) the potential conﬂict between PSA and
computationally expensive model structures is perti-
nent, because the reference case now calls for the use of
PSA as the appropriate way by which the combined
implications of uncertainty in all model parameters be
reﬂected [7].
Although the review is speciﬁc to NICE, issues
relating to the provision of unbiased estimates of costs
and effects and quantifying decision uncertainty, while
reﬂecting the complexity of the disease process and
treatment effect under time and resource constraints,
are more general and relevant to decision models
developed in different contexts.
Review Methods
The review allows an exploration of the potential con-
ﬂict between the use of computationally expensive
model structures and the implementation of PSA in
models submitted to NICE. For the purposes of this
review, computational expense refers to the limited
resources available with which to produce model
results, given the constraints of the decision-making
process. Models may be computationally expensive for
a number of reasons. For our review, the use of
patient-level simulation (PLS) was selected as an indi-
cator of computational expense because its use should
be readily apparent in models submitted to NICE and,
for a given model structure, analysis using PLS is more
computationally expensive than a cohort analysis.
All technology appraisals detailed on the NICE
Web site that were published up until January 2005
were reviewed to identify those where the independ-
ent technology assessment group had utilized a model
structure involving PLS to provide an estimate of
cost-effectiveness. After identifying models that
employed PLS, appraisals published in the same year
were identiﬁed and reviewed. The beneﬁt of compar-
ing models that employed PLS with models published
in the same period is the consistency of constraints
facing model developers. Given the computing
expense of PSA, it might be expected that it would be
more common among models employing a cohort
framework. We identiﬁed common stated reasons for
choosing a PLS rather than a cohort framework, and
assessed their implications for model structure with
respect to uncertainty, variability, and heterogeneity.
For each case study, we ascertained whether a PSA
had been undertaken. In cases where a PSA had not
been undertaken, we explored the availability of alter-
native modeling techniques, such as less computation-
ally expensive modeling structures or emulators. In
those cases where PSA was performed, we discuss the
techniques used.
Uncertainty, Variability, and Heterogeneity
In this section, we distinguish uncertainty, variability,
and  heterogeneity,  explore  the  implications  of  each
for model structure and interpretation of results, and
brieﬂy review the methods available for characterizing
decision uncertainty.
Decision Uncertainty
Decision uncertainty can be regarded as epistemic
uncertainty [8] which relates to model parameters that
have a deﬁnite value, but which cannot be known with
certainty. For example, the risk of future individual
developing cervical cancer has a deﬁnite value, but one
which we can only estimate with uncertainty. This
uncertainty can be characterized with a distribution
and can be reduced with further investigation. Epis-
temic uncertainty is not conﬁned to model parameters,
and may exist in the determination of model structure.
This discussion concentrates on parameter uncertainty,
although it can be generalized to other sources of
uncertainty [9].
The decision to adopt a particular technology
should be based on expected net beneﬁt (NB) so that,
when comparing mutually exclusive treatment strate-
gies for a particular disease area, the optimal strategy
is simply the one with the highest expected NB [10].
Nevertheless, uncertainty is important for two reasons:
1) in nonlinear models, or multilinear models with cor-
related parameters, unbiased estimates of expected NB
require a characterization of uncertainty; and 2) deci-
sions based on expected NB are only appropriate if
there is also some consideration of whether current
evidence is sufﬁcient for allocating health-care
resources, based on an assessment of the consequences
of decision uncertainty [11]. If the decision uncer-
tainty, and/or the consequences of adopting a subop-
timal treatment strategy are large, the decision-maker
may require further evidence on which to base the
adoption decision [4].
Variability
Expected costs and effects are not only uncertain but
also vary across individuals with identical observed
characteristics. This variability can be regarded as
aleatory uncertainty [8] which arises as a result of sto-
chastic variation. It cannot be reduced through meas-
urement, but can be characterized with empirical
distributions. For example, the rate at which an indi-
vidual’s cervical cancer develops will vary between
patients. We can describe the distribution of the rate of
cancer progression by counting the number of patients
who progress at different rates. Nevertheless, further
investigation would not reduce variation in the rate of
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progression. Another example is where, given a prob-
ability of an event occurring, such as death, the reali-
zation of that event can be imagined as being governed
by a lottery. So we may know with certainty that the
probability of death is, for example, 5%, but we do
not know which 5% of people will die.
Variability in itself is not relevant to an adoption
decision based on expected NB. Nevertheless, it may
be necessary to explicitly represent variability in model
structures to obtain an unbiased estimate of expected
NB if, within a patient population which is homoge-
neous in observed baseline characteristics, there is a
nonlinear relationship between a characteristic that
varies between patients and NB.
For example, suppose the outcome of interest, cost
(C), is a nonlinear function of some patient character-
istic (x) with mean, μ, that varies between patients (i)
according to a normal distribution with variance σ:
Ci = kxi2 (1)
xi ∼ N(μ, σ) (2)
The expected value of x across all patients, E[xi], can-
not be used to derive the expected value of C; an esti-
mate of E[xi2] is required because E[xi]2 ≠ E[xi2]. In this
instance, an analysis which failed to account for the
variability in x across patients would provide biased
estimates of expected costs. The use of PLS accounts
for  variability  in  all  included  parameters,  regardless
of whether there exist any nonlinear relationships
between these parameters and model output. Never-
theless, there are a number of other methods by which
we could also address this issue.
For example, by repeatedly sampling from μ and σ
we can estimate E[xi2] as an input to the model. Alter-
natively it may be possible to derive a linear approxi-
mation to the model. That is, we ﬁnd a mathematical
function of μ and σ that gives us E[xi2], that is, deter-
mine function G such that:
E[xi2] = G(μ, σ2) (3)
The requirement to account for variability in model
structure under these circumstances does not negate
the need to estimate decision uncertainty. Failure to
account for uncertainty will also lead to biased esti-
mates of cost and effect in a nonlinear model. Conse-
quently, under these circumstances, both variability
and uncertainty must be characterized in order prop-
erly to inform an adoption decision. In model struc-
tures which are linear with respect to variability but
nonlinear with respect to uncertainty, unbiased esti-
mates of NB require the characterization of uncer-
tainty but not variability. Where models are linear or
multilinear (with independent parameters), it is not
necessary to represent variability or uncertainty to
obtain unbiased estimates of expected NB. Neverthe-
less, it will still be necessary to represent uncertainty in
a model structure to address the question of whether
current evidence provides sufﬁcient basis for the adop-
tion decision.
Heterogeneity
Heterogeneity can be regarded as variation as a result
of observed characteristics on which it is possible to
condition model parameters and therefore expected
NB. Such heterogeneity must be observable at the time
at which the treatment decision is taken. For example,
the risk of developing cervical cancer may depend on
family history. In principle, this can be observed and
subsequent decisions, such as the decision of whether
to screen, based on this observation. This contrasts
with variation in the rate of disease progression which
is unobservable at the time at which the decision to
screen is made. Thus, one could not decide to screen
only those patients whose cancer would develop at a
fast rate. When estimating the cost-effectiveness of an
intervention for a heterogeneous population, one can
condition on the observed characteristics and separate
the overall group into homogenous subpopulations
within which patients have identical observed charac-
teristics. The model can then be run separately for each
homogenous group to generate estimates of cost-
effectiveness conditional on each set of observed char-
acteristics. Adoption decisions can then made for each
of these mutually exclusive and identiﬁable patient
groups [12].
Probabilistic Sensitivity Analysis
In this section, we consider the role of PSA in dealing
with uncertainty in decision models. One- and multi-
way sensitivity analyses cannot reﬂect the combined
uncertainty in all model parameters, and so are inap-
propriate for informing decision uncertainty. PSA,
when conducted properly, provides a more rigorous
approach by requiring that all input parameters in a
model be speciﬁed as full probability distributions,
rather than as point estimates, to indicate the uncer-
tainty of the estimates [13]. PSA can be used accurately
to estimate expected NB in a nonlinear model, and also
to reveal the effect of the combined uncertainty in all
model parameters.
Decisions based on expectation are only appropri-
ate if the consequences of the uncertainty surrounding
the decision are also considered. This informs the nec-
essary question about whether current evidence is suf-
ﬁcient or whether further research is needed. Formal
methods are available to estimate this value of infor-
mation [2] and these are now recommended, although
not required, by NICE. Nevertheless, for the purposes
of this review it is sufﬁcient to note that an appropriate
characterization of decision uncertainty is a prerequi-
site for any assessment of the consequences of decision
uncertainty, whether or not this achieved using formal
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methods. Clearly, decisions based on point estimates
without any consideration of uncertainty will lead to
the adoption of technologies with inadequate and poor
quality evidence [3,10]. Therefore, adoption decisions
cannot be separated from an assessment of whether the
evidence is sufﬁcient to support such decisions. For
example, as well as making the adoption decision,
NICE also makes recommendations for future
research, speciﬁes a review date for guidance, in part
based on when new evidence is expected to be availa-
ble, and has issued guidance conditional on further
evidence being collected to inform future decisions.
Implementing PSA
PSA is commonly conducted using Monte Carlo sim-
ulation. The model is run repeatedly, and each run uses
new random draws from distributions describing the
uncertainty surrounding the value of each of the model
parameters. This propagates parameter uncertainty
through the model, which is then reﬂected in the
results, and can be used to describe the likelihood that
a treatment decision is optimal. This is distinct from
the use of Monte Carlo simulation in PLS where the
model parameters are ﬁxed and a random number is
used to determine the path of each individual patient.
This propagates variability, and sometimes heteroge-
neity, into the model results. Enough simulations must
be run to ensure that this variation does not affect
identiﬁcation of the optimal treatment decision. Thus,
executing PSA within PLS requires a two-level simula-
tion where each set of probabilistic inputs is held con-
stant and the required number of patients is simulated
through the model [14]. This can make PSA an order
of 1,000 or 10,000 more computationally expensive in
a PLS structure as compared with a cohort structure,
and it is sometimes for this reason that PSA is omitted
from models employing PLS.
Alternative methods to conduct PSA exist in the
form of analytical model solutions and emulators. A
closed form solution of expected NB, and possibly the
associated uncertainty, may be tractable. That is, the
analyst could deﬁne a closed-form approximation or
simpliﬁcation that gives the expectation of nonlinear
functions using the model parameters. One such exam-
ple would be the use of a Taylor series expansion [15].
Emulators take the form of nonparametric statistical
models of the outputs of a model, such that those out-
puts can be recalculated with minimal time and com-
putational expense when varying the model inputs
according to the associated uncertainty [14]. Neverthe-
less, there are some limitations associated with the use
of emulators; for example, in the number of uncertain
parameters that may be included. It is not yet known
whether they provide a directly exchangeable alterna-
tive to Monte Carlo simulation. Therefore, the imple-
mentation of PSA through Monte Carlo simulation
can be viewed as current practice.
Results of the Review
The search results are shown in Figure 1. Although not
required by NICE guidance during this period, PSA
was performed in some technology appraisals. One out
of six (17%) models that used PLS, and 16 out of 24
(67%) cohort models conducted PSA. None of the
eight cohort models that omitted PSA cited computa-
tional expense as the reason, whereas two of the PLS
models did. Nevertheless, justiﬁcation for omission of
PSA was not present in the majority of cases.
Case Studies
The review identiﬁed six assessment reports submit-
ted to NICE where the estimates of expected costs
and outcomes were based on a model structure using
PLS. Details of the included appraisals are given in
Table 1.
We identiﬁed four reasons for choosing a PLS struc-
ture over a cohort framework. These were treatment
switching, sampling from patient characteristics,
dependence on patient history, including previous
events and time-in-state, and uncertainty and variabil-
ity. The following review section provides a more
detailed description of these reasons in the context of
their use in the case studies, and assesses their impli-
cations for model structure.
Treatment Switching
In some disease areas, patients will be treated with a
sequence of interventions. These may involve different
drugs or different dosages of the same drugs. The deci-
sion regarding whether to move a patient to the next
treatment in a sequence may be based on patient char-
acteristics or patient history and therefore subject to
variability. Nevertheless, for a given set of eligibility
criteria for treatment switching, there will not be
uncertainty around whether a patient proceeds to the
next treatment. In other words, patients may vary in
their characteristics and history, and as a result there
will be variation in the number of patients switching
treatment, but for a given set of characteristics and his-
tory there will not be random variation in the number
of patients switching.
Case study 1 assessed the cost-effectiveness of imat-
inib for gastrointestinal stromal tumors (GIST) [16].
Current guidelines at the time of the assessment rec-
ommended an initial dose of 400 mg daily, with the
option of proceeding to a higher dose in the event of a
poor response or disease progression, and withdrawal
of treatment in the absence of beneﬁt after 8 weeks.
Nevertheless, because of a paucity of data, the best
starting dose of imatinib and best treatment pattern
were highly uncertain.
The model had four health states: progressive dis-
ease, treatment with 400 mg imatinib, treatment with
600 mg imatinib and death. Patients in the imatinib
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treatment group began with 400 mg daily: patients
whose disease progressed could move to 600 mg daily,
or move to the progressive disease state. Patients who
failed treatment with 600 mg imatinib daily moved to
the progressive disease state, from which the only tran-
sitions were to remain in state or die. Patients could die
at any stage in the model. Patients in the control group
(i.e., no imatinib) began the model in the progressive
disease state, and could remain in state or die. The
cycle length was 4 weeks, and the time horizon was
10 years.
For those patients who failed to respond to 400 mg
imatinib, a random number was generated to deter-
mine whether they would be moved to 600 mg, or
straight to the progressive disease state. The probabil-
ity of receiving 600 mg was based on the number of
patients who had responded after crossing over from
400 mg to 600 mg imatinib in a clinical trial [17].
In reality, the decision to move from a dose of
400 mg to 600 mg would not be based on random
chance. Although there may be uncertainty about the
number of patients who would respond to 600 mg
after progressing on 400 mg imatinib, this could not be
identiﬁed before the treatment decision being taken.
The treatment strategy in practice would involve mov-
ing all eligible patients onto 600 mg. When response is
Figure 1 Search results. *Two cost-minimiza-
tion analyses, two considered the cost results
alongside trial results; †One meta-model of
industry submission, one model type unclear.
PSA, probabilistic sensitivity analysis.
Published appraisals January 2002–January
2005
Included model developed by independent
assessment group
40
Patient-level
simulation
6 (1 PSA)
Cohort
24 (16 PSA)
Cost analysis*
4 (0 PSA)
Other†
2 (0 PSA)
Decision tree
4 (0 PSA)
Table 1 Examples of the use of patient-level simulation in NICE assessment reports
Case 
study Title
Gave justiﬁcation for
choice of PLS?
Estimate decision
uncertainty?
1 Imatinib for the treatment of patients with unresectable and/or metastatic 
gastrointestinal stromal tumors—a systematic review and economic 
evaluation [18]
Yes No
2 The clinical effectiveness and cost effectiveness of prevention and treatment of 
osteoporosis [20]
Yes Yes
3 The effectiveness of inﬂiximab and etanercept for the treatment of rheumatoid 
arthritis: a systematic review and economic evaluation [22]
Yes No
4 The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid 
arthritis in adults [23]
Yes No
5 The clinical effectiveness and cost-effectiveness of newer drugs for children 
with epilepsy [24]
Yes No
6 Coronary artery stents: rapid systematic review & economic evaluation [29] No No
NICE, National Institute for Clinical Excellence; PLS, patient level simulation.
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assessed after 4 weeks, those patients not responding,
as observed in the clinical trial, would then move to the
progressive state. This could be compared with a strat-
egy of not moving patients to a higher dose of the drug
after failure on 400 mg. This alternative approach was
taken by the developers of the GIST model in a sub-
sequent evaluation. This approach enables decisions to
be made about the best treatment pattern, rather than
including current variability in treatment patterns in
the model results. The situation where variability in
patient characteristics may introduce uncertainty into
the number of patients switching treatment is dis-
cussed in the later section on patient histories.
Sampling Baseline Patient Characteristics
Many characteristics of interest will vary between
patients with the same disease, and some will be
observable at the time at which the treatment decision
is made. In other words, they are observable, able to be
measured with precision, at baseline. If these charac-
teristics determine the likelihood of future events,
parameters in the model will depend on that observa-
tion. It is important to separate the heterogeneous pop-
ulation into homogenous subgroups, and to model
these groups separately; otherwise the results of the
model relate to the average patient, that is, the mean of
the distributions describing the variation of the char-
acteristics of interest. In practice, the treatment deci-
sion can and should be made conditional on the
observed characteristic of each patient, not the
expected characteristic.
Case study 2 considers treatments for osteoporosis
for primary and secondary prevention of fractures
[18]. The model is an update of a previously con-
structed model by the same assessment group [19].
This, in effect, relaxes the time constraint normally
imposed on the development of such models for NICE.
The structure of the model is described as being similar
to  a  Markov  model  with  a  cycle  length  of  1 year,
the difference being that patients are entered into the
model individually, and their history is tracked. The
states in the secondary prevention model are hip frac-
ture, wrist fracture, vertebral fracture, proximal
humerus fracture, breast cancer, coronary heart dis-
ease, and death. The model also tracks the residential
status of each patient to assign costs. The authors state
the belief that reﬂecting the increased risk of recurrent
fractures after an initial fracture, and tracking the res-
idential status of patients in the model, would be
difﬁcult in a cohort model.
The  secondary  prevention  model  considers  the
cost-effectiveness of treatment strategies for women
presenting at baseline with hip, vertebral, wrist or
proximal humerus fractures. Thus, the PLS is
employed, in part, to track the presenting fracture site
for each woman, because the model assumes a differ-
ent baseline risk of subsequent fractures for each initial
fracture site. Because of the difference in baseline risk
of future events for each initial fracture site, and the
fact that this characteristic is known when the treat-
ment decision is taken, these could have been assessed
as separate subgroups; it is important to be able to
make separate treatment recommendations for each
group. This would considerably reduce the number of
states required to represent that portion of the model
in a cohort framework. This alternative represents a
different characterization of the decision problem
which justiﬁes a simpliﬁcation of the model structure.
This conditioning on baseline characteristics is distinct
from conditioning on events that occur throughout the
model process, for example, the location of new frac-
ture sites after treatment has been initiated. In this
example, the PLS model structure was also used to
record patient history in the model, and this issue is the
focus of the next section on patient histories.
Dependence on Patient Histories
Observable variation within groups homogenous in
baseline characteristics may arise as a result of subse-
quent events that occur within the model structure. To
condition model parameters on this observed varia-
tion, it is necessary to record these events in some way.
The method with which to do this will depend on the
choice of model structure.
Case studies 3 and 4 examined treatments for rheu-
matoid arthritis [20,21]. There is a low likelihood of
long-term use for any one disease-modifying antirheu-
matic drug (DMARD), because they are not always
effective, lose effectiveness over time, or cause adverse
effects. Case study 5 assessed the cost-effectiveness of
“newer” antiepileptic drugs (AEDs) in children [22].
Lack of effect on seizure rate and intolerable side
effects means that many patients with epilepsy are
treated with a sequence of drugs. The models com-
pared ﬁxed treatment sequences. The discontinuation
rate of each treatment was modeled as a Weibull dis-
tribution with a shape parameter not equal to one (i.e.,
the  hazard  rate  was  not  constant).  In  other  words,
the probability of discontinuing each treatment was
dependent on the time spent on that treatment. Also,
the availability of future treatment options was
affected by toxic reactions to previous drugs. The PLS
structure allows the analyst to record the realized time
spent receiving each drug for each individual patient.
A separate assessment examined the use of newer
AEDs in adults [23]. The decision problem and the
events to be reﬂected in the model were very similar to
the model of AEDs in children. As with case studies 3,
4, and 5, time to treatment discontinuation was a func-
tion of time spent on the drug, but this was facilitated
in a cohort model by employing a semi-Markov frame-
work. This semi-Markov model was built in the
statistical programming language R [24], which can
manipulate n-dimensional arrays and track the time
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spent in each state. This alternative model structure
enabled PSA to be undertaken to provide an estimate
of decision uncertainty, without sacriﬁcing the time-
dependent structure of the model.
Probabilistic Sensitivity Analysis with PLS
As can be seen in Table 1, case study 2 formally
assessed decision uncertainty [18]. This was made fea-
sible through the use of an emulator employing Gaus-
sian processes [14]. The full model was run 80 times
using different values for the inputs to estimate a non-
parametric relationship between the input parameters
and the outputs of the model. This “model of a model”
could then be analyzed relatively quickly to produce
an estimate of decision uncertainty. The use of 80 runs
of the model, as compared with perhaps 10,000 runs
for PSA, considerably reduces the computing power
and time required to estimate decision uncertainty
within a PLS model structure.
Discussion
If it is accepted that adoption decisions should be made
with consideration of the associated decision uncer-
tainty, then we may say that models submitted to
decision-makers have a dual requirement to estimate
expected NB and characterize decision uncertainty.
The use of PLS is often justiﬁed with reference to the
ﬁrst of these. In other words, the claim is made that it
would not be possible to estimate NB accurately using
a cohort framework for that particular decision prob-
lem. In our review, we have identiﬁed four reasons for
choosing PLS, and showed that none of these neces-
sarily preclude the use of a cohort framework. We have
also identiﬁed an example where a formal estimate of
decision uncertainty was obtained alongside a compu-
tationally expensive PLS model structure, showing that
the two are not mutually exclusive.
This review indicates that the most common justi-
ﬁcations for choosing a PLS are the need to incorpo-
rate time and history dependence in transition
probabilities. In a Markov model, these would be han-
dled using tunnel states, and if the number of states
required is very large, the Markov framework may
become unwieldy and inefﬁcient. An alternative was
illustrated whereby time- and state-dependent transi-
tions were represented in a cohort framework using
semi-Markov processes [25,26]. To employ this
method to track elements of patient history within a
cohort framework, it may be necessary to build the
model in appropriate software. The use of alternative
software can provide ﬂexibility to design an alternative
model structure, and may also reduce analysis time.
This is no panacea, because there will be limits to the
gain in analysis time available with alternative soft-
ware, and improved hardware. For example, in the
updated rheumatoid arthritis case study [21], the use
of Borland Delphi [27] instead of TreeAge DATA 3.5
[28] sped up the analysis. Nevertheless, in this partic-
ular case the gain in analysis time was not enough to
facilitate PSA. Dissemination and training are also
required to allow further use of alternative software,
and this may represent an additional constraint.
Time- and state-dependent transitions are easily
handled within PLS. If the use of Monte Carlo simu-
lation to conduct PSA is too computationally ex-
pensive, the requirement to characterize decision
uncertainty could still be met, as evidenced by the use
of an emulator in one case study [18]. Nevertheless, the
use of emulators is still in development, and there are
currently some limitations, for example, in the number
of uncertain input parameters that can be included.
More research is necessary to validate such models
before it is known whether they are exchangeable with
conducting PSA by means of Monte Carlo simulation.
We have shown that where there is a nonlinear rela-
tionship between a characteristic that varies between
patients and the model output, it is necessary to
account for this variability. This is distinct from the
issue of baseline patient characteristics that confer a
different baseline risk of subsequent events (heteroge-
neity), but refers to variability within homogenous
patient subgroups. Importantly, this does not counter
the need to address decision uncertainty because any
nonlinear model which requires an assessment of var-
iability will also need to assess uncertainty to estimate
expected NB. A PLS can address the issue of variabil-
ity, but this can also be addressed within a cohort
framework by employing a two-level simulation. A
third way to address this issue would be to ﬁnd a
closed-form approximation to the model which sim-
pliﬁes the analysis greatly. The alternatives identiﬁed
here should allow the same level of detail in charac-
terizing the decision problem as is possible with a PLS
framework, but with lower computational expense.
Nevertheless, they do require specialized knowledge to
be able to correctly model that decision problem.
So how generalizable are the results of the review
detailed here? An increasing number of models in the
literature have been developed for—or to inﬂuence—a
speciﬁc decision-making body at a particular point in
time. Such models are typically developed with similar
constraints as the models for NICE described here.
Some models are developed over a longer-time period,
and perhaps with more generous funding. Usually such
analyses are not concerned with the decision problem
of a particular organization, but have a wider set of
aims and objectives. Nevertheless, even models devel-
oped in this way still face binding resource and time
constraints, not least from the research funder. Fur-
thermore, the purpose of all decision models is ulti-
mately to inform real decisions at some point in time.
Therefore, all analysts will simultaneously have to
tackle the tasks of quantifying decision uncertainty
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while reﬂecting the complexity of the disease process
and effect of the intervention under time and resource
constraints. Hence, the general issues highlighted by
the NICE case studies are relevant to decision models
developed in different contexts.
In conclusion, if the dual requirement of models to
estimate NB and to characterize decision uncertainty is
accepted, then the failure to fulﬁll the latter require-
ment will limit its value for decision-making. The
claim that a model has been structured to provide a
more appropriate estimate of expected NB but is too
complex for PSA given the analysts’ constraints would
leave the decision-maker without a key element of
information. There are often alternative modeling
approaches to handle particular characteristics of a
decision problem that can be used to reduce the com-
plexity of the model, or to facilitate the conduct of PSA
within a complex model structure, and both of these
do not reduce the ability of the analyst to estimate NB
correctly. This makes it possible to produce probabil-
istic models to estimate expected NB and characterize
decision uncertainty within the constraints of the deci-
sion-making process.
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